Cargando…
Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics
Immune checkpoints and other immunoregulatory targets can be difficult to precisely target due to expression on non-tumor immune cells critical to maintaining immune homeostasis in healthy tissues. On-target/off-tumor binding of therapeutics results in significant pharmacokinetic and pharmacodynamic...
Autores principales: | Smith, F. Donelson, Pierce, Robert H., Thisted, Thomas, van der Horst, Edward H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525963/ https://www.ncbi.nlm.nih.gov/pubmed/37753969 http://dx.doi.org/10.3390/antib12030055 |
Ejemplares similares
-
Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody
por: Gao, Han, et al.
Publicado: (2020) -
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
por: Dahal, Lekh N., et al.
Publicado: (2016) -
Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors
por: Chmiel, Paulina, et al.
Publicado: (2023) -
Polymorphic Sites at the Immunoregulatory CTLA-4 Gene Are Associated with Chronic Chagas Disease and Its Clinical Manifestations
por: Dias, Fabrício C., et al.
Publicado: (2013) -
Agonistic nanobodies and antibodies to human VISTA
por: Ma, Yu-Heng Vivian, et al.
Publicado: (2021)